このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

H. Lundbeck 配当金

配当金基準チェック /36

H. Lundbeck配当を支払う会社であり、現在の利回りは1.84%で、収益によって十分にカバーされています。

主要情報

1.8%

配当利回り

29%

配当性向

業界平均利回り	2.2%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	DKK 2.44
3年後の配当利回り予想	3.1%

最近の配当金アップデート

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

Recent updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

決済の安定と成長

配当データの取得

安定した配当: HLUN Bは配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。

増加する配当: HLUN Bは配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。

配当利回り対市場

H. Lundbeck 配当利回り対市場

HLUN B 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (HLUN B)	1.8%
市場下位25% (DK)	1.7%
市場トップ25% (DK)	5.7%
業界平均 (Pharmaceuticals)	2.2%
3年後のアナリスト予想 (HLUN B)	3.1%

注目すべき配当: HLUN Bの配当金 ( 1.84% ) はDanish市場の配当金支払者の下位 25% ( 1.67% ) よりも高くなっています。

高配当: HLUN Bの配当金 ( 1.84% ) はDanish市場の配当金支払者の上位 25% ( 5.77% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: HLUN Bの配当性向 ( 28.8% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。

株主配当金

キャッシュフローカバレッジ: HLUN Bは低い現金配当性向 ( 16.8% ) であるため、配当金の支払いはキャッシュフローによって十分にカバーされています。

H. Lundbeck 配当金

配当金 基準チェック /36

主要情報

最近の配当金アップデート

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

H. Lundbeck A/S Proposes Dividend for 2022

Recent updates

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /36